Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Facility Design

Analytics Overview

100
Form 483s Issued
11
483s converted to WL
131
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
19 Nov 2024
Dr. Reddy's Laboratories Limited (Unit II)
Drugs
25 Sep 2024
Nephron Sterile Compounding Center LLC
Drugs
06 Sep 2024
Granules India Limited
Drugs
06 Sep 2024
Granules India Limited
Drugs
06 Sep 2024
Mark Cuban Cost Plus Manufacturing and Compounding LLC
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
9
1
Camerson E Moore
8
0
Margaret M Annes
8
4
Christopher R Czajka
7
0
Edmund F Mrak
7
2
TITLE/ COMPANY Issue Date Status Details
Buildings used in the manufacturing of Intermediates and finished APIs are not maintained in a good state of repair.
Dr. Reddy's Laboratories Limited (Unit II)
19 Nov 2024 Normal Justification: The observation highlights poor maintenance which is a fundamental aspect of facility design affecting production areas.
Excerpt: Buildings used in the manufacturing of Intermediates and finished APIs are not maintained in a good state of repair.
View Details
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
Nephron Sterile Compounding Center LLC
25 Sep 2024 Normal Justification: Facility Design impacts environmental controls; absence of indicators between rooms is a design shortcoming.
Excerpt: There was no alarm, light, or device providing an indication and measurement of a change in differential pressure.
View Details
Aseptic processing areas are deficient in that are not smooth and/or hard surfaces that are easily cleanable.
Nephron Sterile Compounding Center LLC
25 Sep 2024 Normal Justification: The observation details surface damage and residue, indicating that facility design elements like materials used are not fit.
Excerpt: Aseptic processing areas are deficient in that are not smooth and/or hard surfaces that are easily cleanable.
View Details
Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction
Mark Cuban Cost Plus Manufacturing and Compounding LLC
06 Sep 2024 Normal Justification: The issue is directly linked to facility design due to improper infrastructure allowing contamination risks.
Excerpt: Your firm's ISO 7 Filling Room (RM 034) containing your ISO 5 (b) (4) Fill (b) (4) is designed with exposed sprinkler heads within the room ceiling.
View Details
Building and facilities are not maintained to ensure that products manufactured meet the quality
Granules India Limited
06 Sep 2024 Normal Justification: Observation discusses poor facility maintenance, specifically mentioning damaged filters and contaminated areas.
Excerpt: filters of vour randomly selected Air Purification Units... were severely damaged and torn in many sections.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.